Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas With Met Fusion Gene
Apollomics宣布Vebreltinib在中国获准作为首创的具有Met Fusion基因的神经胶质瘤治疗药物
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas With Met Fusion Gene
Apollomics宣布Vebreltinib在中国获准作为首创的具有Met Fusion基因的神经胶质瘤治疗药物
使用浏览器的分享功能,分享给你的好友吧